Because retatrutide is investigational, there is no approved standard dosing schedule for general public use
Ipamorelin provides selective, clean GH stimulation through ghrelin receptor activation
However, in clinical trials, participants typically began to see weight loss results within the first few weeks of starting treatment
Weight loss accelerates compared to the first month, with most participants now seeing consistent weekly drops on the scale
According to the FDA prescribing information, tirzepatide is associated with modest increases in heart rate (average 2-4 beats per minute), consistent with the class effect observed with GLP-1 receptor agonists
The molecular design that enables weekly dosing Retatrutide incorporates a C20 fatty diacid moiety that binds to serum albumin in the bloodstream